[1] JANAGAM D R, WU L, LOWE T L. Nanoparticles for drug delivery to the anterior segment of the eye[J]. Adv Drug Deliv Rev,2017,122:31-64.
[2] CAMPOCHIARO P A, HACKETT S F. Ocular neovascularization: a valuable model system[J]. Oncogene,2003,22(42):6537-6548.
[3] MELNIKOVA I. Wet age-related macular degeneration[J]. Nat Rev Drug Discov,2005,4(9):711-712.
[4] SMITH A G, KAISER P K. Emerging treatments for wet age-related macular degeneration[J]. Expert Opin Emerg Drugs,2014,19(1):157-164.
[5] KAISER P K. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline[J]. Ophthalmology,2013,120(5):S11-S15.
[6] TAO W. Application of encapsulated cell technology for retinal degenerative diseases[J]. Expert Opin Biol Ther, 2006, 6(7):717-726.
[7] BATTAGLIA L, SERPE L, FOGLIETTA F. Application of lipid nanoparticles to ocular drug delivery[J]. Expert Opin Drug Del,2016,13(12):1743-1757.
[8] BASHIR H, SEYKORA J T, LEE V. Invisible shield: review of the corneal epithelium as a barrier to UV radiation, pathogens, and other environmental stimuli[J]. J Ophthalmic Vis Res,2017,12(3):305-311.
[9] EDWARD A, PRAUSNITZ M R. Predicted permeability of the cornea to topical drugs[J]. Pharm Res,2001,18(11):1497-1508.
[10] MAICHUK I, IUZHAKOV A M, LIUDOVSKAIA L A. Relation between pharmacokinetics of an antibiotic in ocular fluids and the method of administration and dosage form of gentamycin[J]. Antibiotiki,1984,29(5):386-390.
[11] RAVIOLA G. The structural basis of the blood-ocular barriers[J]. Exp Eye Res,1977,25:27-63.
[12] DEL A E, RIMPELA A K, HEIKKINEN E. Pharmacokinetic aspects of retinal drug delivery[J]. Prog Retin Eye Res,2017,57:134-185.
[13] PITKANEN L, RANTA V P, MOILANEN H. Permeability of retinal pigment epithelium: effects of permeant molecular weight and lipophilicity[J]. Invest Ophthalmol Vis Sci,2005,46(2):641-646.
[14] HIRAL J, SHAH J N S. Nanoparticulate transscleral ocular drug delivery[J]. J Biomol Res Ther,2014,3(3):1-14.
[15] EDELHAUSER H F, ROWE-RENDLEMAN C L, ROBINSON M R. Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications[J]. Invest Ophthalmol Vis Sci,2010,51(11):5403-5420.
[16] GAUDANA R, JWALA J, BODDU S H. Recent perspectives in ocular drug delivery[J]. Pharm Res,2009,26(5):1197-1216.
[17] DANIS R, MCLAUGHLIN M M, TOLENTINO M. Pazopanib eye drops: a randomised trial in neovascular age-related macular degeneration[J]. Br J Ophthalmol,2014,98(2):172-178.
[18] SUDA K, MURAKAMI T, GOTOH N. High-density lipoprotein mutant eye drops for the treatment of posterior eye diseases[J]. J Controlled Release,2017,266:301-309.
[19] GREEN M, LOEWENSTEIN P M. Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein[J]. Cell,1988,55(6):1179-1188.
[20] LEIFERT J A, WHITTON J L. "Translocatory proteins" and "protein transduction domains": a critical analysis of their biological effects and the underlying mechanisms[J]. Mol Ther,2003,8(1):13-20.
[21] KAMEI N, MORISHITA M, EHARA J. Permeation characteristics of oligoarginine through intestinal epithelium and its usefulness for intestinal peptide drug delivery[J]. J Controlled Release,2008,131(2):94-99.
[22] LI Y, LI L, LI Z. Tat PTD-Endostatin-RGD: a novel protein with anti-angiogenesis effect in retina via eye drops[J]. Biochim Biophys Acta,2016,1860(10):2137-2147.
[23] ZHANG X, LI Y, CHENG Y. Tat PTD-endostatin: a novel anti-angiogenesis protein with ocular barrier permeability via eye-drops[J]. Biochim Biophys Acta,2015,1850(6):1140-1149.
[24] JANORIA K G, GUNDA S, BODDU S H. Novel approaches to retinal drug delivery[J]. Expert Opin Drug Deliv,2007,4(4):371-388.
[25] CONLEY S M, NAASH M I. Nanoparticles for retinal gene therapy[J]. Prog Retin Eye Res,2010,29(5):376-397.
[26] GAUDANA R, ANANTHULA H K, PARENKY A. Ocular drug delivery[J]. Aaps J,2010,12(3):348-360.
[27] WEIJTENS O, SCHOEMAKER R C, LENTJES E G. Dexamethasone concentration in the subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose[J]. Ophthalmology,2000,107(10):1932-1938.
[28] RANTA V P, URTTI A. Transscleral drug delivery to the posterior eye: prospects of pharmacokinetic modeling[J]. Adv Drug Deliv Rev,2006,58(11):1164-1181.
[29] CHIANG B, JUNG J H, PRAUSNITZ M R. The suprachoroidal space as a route of administration to the posterior segment of the eye[J]. Adv Drug Deliv Rev,2018,126:58-66.
[30] TETZ M, RIZZO S, AUGUSTIN A J. Safety of submacular suprachoroidal drug administration via a microcatheter: retrospective analysis of european treatment results[J]. Ophthalmologica,2012,227(4):183-189.
[31] KATO A, KIMURA H, OKABE K. Suppression of laser-induced choroidal neovascularization by posterior sub-tenon administration of triamcinolone acetonide[J]. Retina,2005,25(4):503-509.
[32] KATOME T, NAITO T, NAGASAWA T. Efficacy of combined photodynamic therapy and sub-Tenon's capsule injection of triamcinolone acetonide for age-related macular degeneration[J]. J Med Invest,2009,56(3-4):116-119.
[33] YOSHIZAWA C, SAITO W, HIROSE S. Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration[J]. Jpn J Ophthalmol,2013,57(1):68-73.
[34] LEVIN D S, HAN D P, DEV S. Subtenon's depot corticosteroid injections in patients with a history of corticosteroid-induced intraocular pressure elevation[J]. Am J Ophthalmol,2002,133(2):196-202.
[35] CARRASQUILLO K G, RICKER J A, RIGAS I K. Controlled delivery of the anti-VEGF aptamer EYE001 with poly(lactic-co-glycolic)acid microspheres[J]. Invest Ophthalmol Vis Sci,2003,44(1):290-299.
[36] O'NEIL E C, HUANG J, SUHLER E B. Iontophoretic delivery of dexamethasone phosphate for non-infectious, non-necrotising anterior scleritis, dose-finding clinical trial[J]. Br J Ophthalmol,2018,102(8):1011-1013.
[37] GRATIERI T, SANTER V, KALIA Y N. Basic principles and current status of transcorneal and transscleral iontophoresis[J]. Expert Opin Drug Deliv,2017,14(9):1091-1102.
[38] THANOS C G, BELL W J, O'ROURKE P. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device[J]. Tissue Eng,2004,10(11-12):1617-1622.
[39] LIM J I, NIEC M, WONG V. One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD[J]. Br J Ophthalmol,2015,99(5):618-623.
[40] RUPENTHAL I D. Drug-device combination approaches for delivery to the eye[J]. Curr Opin Pharmacol,2017,36:44-51.
[41] QUERQUES L, QUERQUES G, LATTANZIO R. Repeated intravitreal dexamethasone implant [Ozurdex(R)] for retinal vein occlusion[J]. Ophthalmologica,2013,229(1):21-25.
[42] CAPUANO V, SERRA R, OUBRAHAM H. Dexamethasone intravitreal implant for choroidal neovascularization during pregnancy[J]. Retin Cases Brief Rep,2017:1.
[43] GIANCIPOLI E, PINNA A, BOSCIA F. Intravitreal dexamethasone in patients with wet age-related macular degeneration resistant to anti-VEGF: a prospective pilot study[J]. J Ophthalmol,2018,2018(9):1-8.
[44] SUN R, TANG Z, WANG Q. New dosage forms for ocular administration[J]. Chin Pharm J(中国药学杂志), 2016,51(23):1993-1998.
[45] PECHAN P, RUBIN H, LUKASON M. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization[J]. Gene Ther,2009,16(1):10-16.
[46] HEIER J S, KHERANI S, DESAI S. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial[J]. Lancet,2017,390(10089):50-61.
[47] FITZGERALD J T, SAUNDERS L, RIDGE B. Severe intraocular pressure response to periocular or intravitreal steroid treatment in Australia and New Zealand: data from the Australian and New Zealand Ophthalmic Surveillance Unit[J]. Clin Exp Ophthalmol,2015,43(3):234-238.
[48] MUHLFRIEDEL R, MICHALAKIS S, GARCIA G M. Optimized technique for subretinal injections in mice[J]. Methods Mol Biol,2013,935:343-349.
[49] GHAZI N G, ABBOUD E B, NOWILATY S R. Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector: results of a phase I trial[J]. Hum Genet,2016,135(3):327-343.
[50] TESTA F, MAGUIRE A M, ROSSI S. Three-year follow-up after unilateral subretinal delivery of adeno-associated virus in patients with Leber congenital amaurosis type 2[J]. Ophthalmology,2013,120(6):1283-1291.
[51] GORDON K, DEL M A, SANDER I. Gene therapies in ophthalmic disease[J]. Nat Rev Drug Discov,2019,18:415-416.
[52] PENG Y, TANG L, ZHOU Y. Subretinal injection: a review on the novel route of therapeutic delivery for vitreoretinal diseases[J]. Ophthalmic Res,2017,58(4):217-226.
[53] CAMPOCHIARO P A, LAUER A K, SOHN E H. Lentiviral vector gene transfer of endostatin/angiostatin for macular degeneration (GEM) study[J]. Hum Gene Ther,2017,28(1):99-111.
[54] CONSTABLE I J, PIERCE C M, LAI C M. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration[J]. Ebiomed,2016,14:168-175.
[55] HUSSAIN R M, CIULLA T A. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration[J]. Expert Opin Emerg Drugs,2017,22(3):235-246.